Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) Short Interest Up 107.6% in June

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) was the recipient of a large growth in short interest during the month of June. As of June 15th, there was short interest totaling 27,250 shares, a growth of 107.6% from the May 31st total of 13,125 shares. Based on an average daily trading volume, of 24,781 shares, the short-interest ratio is currently 1.1 days. Approximately 1.6% of the company’s shares are sold short.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on BOLT shares. HC Wainwright reissued a “buy” rating and issued a $7.00 price target on shares of Bolt Biotherapeutics in a research note on Thursday, May 28th. Rodman & Renshaw began coverage on Bolt Biotherapeutics in a research note on Thursday, May 28th. They issued a “buy” rating and a $22.00 price objective on the stock. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Bolt Biotherapeutics in a report on Monday, April 20th. Three analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $34.67.

Bolt Biotherapeutics Trading Up 7.4%

Shares of BOLT traded up $0.29 during trading hours on Tuesday, hitting $4.19. 2,122 shares of the stock were exchanged, compared to its average volume of 27,182. Bolt Biotherapeutics has a fifty-two week low of $3.75 and a fifty-two week high of $7.20. The business has a 50-day moving average of $4.69 and a 200-day moving average of $5.01. The firm has a market capitalization of $8.04 million, a P/E ratio of -0.26 and a beta of 1.12. The company has a debt-to-equity ratio of 0.98, a current ratio of 3.51 and a quick ratio of 3.51.

Bolt Biotherapeutics (NASDAQ:BOLT) last released its earnings results on Tuesday, May 12th. The company reported ($4.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.85) by ($1.46). The firm had revenue of $0.03 million during the quarter, compared to analyst estimates of $1.50 million. Bolt Biotherapeutics had a negative net margin of 455.15% and a negative return on equity of 100.89%. On average, research analysts expect that Bolt Biotherapeutics will post -11.1 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Renaissance Technologies LLC boosted its position in shares of Bolt Biotherapeutics by 40.3% during the 1st quarter. Renaissance Technologies LLC now owns 77,225 shares of the company’s stock valued at $312,000 after purchasing an additional 22,200 shares in the last quarter. T3 Companies LLC acquired a new stake in Bolt Biotherapeutics during the fourth quarter worth approximately $208,000. Nano Cap New Millennium Growth Fund L P bought a new stake in Bolt Biotherapeutics in the fourth quarter worth approximately $112,000. Susquehanna International Group LLP bought a new stake in Bolt Biotherapeutics in the third quarter worth approximately $89,000. Finally, Shay Capital LLC acquired a new position in Bolt Biotherapeutics in the third quarter valued at approximately $85,000. 86.70% of the stock is owned by institutional investors and hedge funds.

About Bolt Biotherapeutics

Bolt Biotherapeutics is a clinical-stage immuno-oncology company focused on developing novel targeted therapies that engage both innate and adaptive immune responses against cancer. The company’s proprietary Biologics-Driven Checkpoint (BDC) platform combines tumor-targeting antibodies with innate immune agonists to activate antigen-presenting cells within the tumor microenvironment, thereby promoting robust T-cell mediated tumor cell killing. Its lead candidate, BDC-1001, couples a HER2-directed monoclonal antibody with a Toll-like receptor 7/8 agonist and is currently in Phase I clinical trials for HER2-positive solid tumors.